cobicistat

chemical compound

Uses your system voice; voice and rate in settings.

Q5138908Snapshot

≈ 5 min read

Names in other languages

  • fikobisistaatti
  • Magyarkobicisztát
  • العربيةكوبيسيستات
  • Englishcobicistat
  • Nederlandscobicistat
  • shKobicistat
  • slkobicistat
  • СрпскиKobicistat

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 451564721 | IUPAC_name = 1,3-thiazol-5-ylmethyl [(2R,5R)-5- {[(2S)-2-[(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)amino]-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate | image = Cobicistat structure.svg | image_class = skin-invert-image | width = 275 | drug_name = | pronounce = | tradename = Tybost | Drugs.com = | MedlinePlus = a616029 | licence_EU = yes | licence_US = | DailyMedID = Cobicistat | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | legal_status = | dependency_liability = | routes_of_administration = | ATC_prefix = V03 | ATC_suffix = AX03 | ATC_supplemental = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | IUPHAR_ligand = 7535 | CAS_number_Ref = | CAS_number = 1004316-88-4 | ChEMBL_Ref = | ChEMBL = 2095208 | PubChem = 25151504 | DrugBank_Ref = | DrugBank = DB09065 | ChEBI_Ref = | ChEBI = 72291 | ChemSpiderID_Ref = | ChemSpiderID = 25084912 | UNII_Ref = | UNII = LW2E03M5PG | KEGG_Ref = | KEGG = D09881 | synonyms = GS-9350 | C=40 | H=53 | N=7 | O=5 | S=2 | SMILES = CC(C)c1nc(cs1)CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(Cc3ccccc3)NC(=O)OCc4cncs4)Cc5ccccc5 | StdInChI_Ref = | StdInChI = 1S/C40H53N7O5S2/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(1…

{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 451564721 | IUPAC_name = 1,3-thiazol-5-ylmethyl [(2R,5R)-5- {[(2S)-2-[(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)amino]-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate | image = Cobicistat structure.svg | image_class = skin-invert-image | width = 275 | drug_name = | pronounce = | tradename = Tybost | Drugs.com = | MedlinePlus = a616029 | licence_EU = yes | licence_US = | DailyMedID = Cobicistat | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | legal_status = | dependency_liability = | routes_of_administration = | ATC_prefix = V03 | ATC_suffix = AX03 | ATC_supplemental = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | IUPHAR_ligand = 7535 | CAS_number_Ref = | CAS_number = 1004316-88-4 | ChEMBL_Ref = | ChEMBL = 2095208 | PubChem = 25151504 | DrugBank_Ref = | DrugBank = DB09065 | ChEBI_Ref = | ChEBI = 72291 | ChemSpiderID_Ref = | ChemSpiderID = 25084912 | UNII_Ref = | UNII = LW2E03M5PG | KEGG_Ref = | KEGG = D09881 | synonyms = GS-9350 | C=40 | H=53 | N=7 | O=5 | S=2 | SMILES = CC(C)c1nc(cs1)CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(Cc3ccccc3)NC(=O)OCc4cncs4)Cc5ccccc5 | StdInChI_Ref = | StdInChI = 1S/C40H53N7O5S2/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49)/t32-,33-,36+/m1/s1 | StdInChIKey_Ref = | StdInChIKey = ZCIGNRJZKPOIKD-CQXVEOKZSA-N | density = | melting_notes = | solubility = | specific_rotation = }} Cobicistat, sold under the brand name Tybost, is a medication for use in the treatment of human immunodeficiency virus infection (HIV/AIDS). Its major mechanism of action is through the inhibition of human CYP3A proteins.

Like ritonavir (Norvir), cobicistat is of interest for its ability to inhibit liver enzymes that metabolize other medications used to treat HIV, notably elvitegravir, an HIV integrase inhibitor. By combining cobicistat with elvitegravir, higher concentrations of the latter are achieved in the body with lower dosing, theoretically enhancing elvitegravir's viral suppression while diminishing its adverse side-effects.

In contrast with ritonavir, the only other booster approved for use as a part of HAART, cobicistat has no anti-HIV activity of its own. Cobicistat is a component of three four-drug, fixed-dose combination HIV treatments. The first, elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil, is marketed as Stribild and was approved by the FDA in August 2012 for use in the United States.

The second, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, is marketed as Genvoya and was approved by the FDA in November 2015 for use in the United States. Both Stribild and Genvoya are owned by Gilead Sciences.

The third, cobicistat/darunavir/emtricitabine/tenofovir alafenamide, is marketed as Symtuza and was FDA approved July 17, 2018 and is owned by Janssen Pharmaceuticals. Additionally, there is a fixed-dose combination of cobicistat and the protease inhibitor darunavir (darunavir/cobicistat; marketed as Prezcobix by Janssen Therapeutics), and a fixed-dose combination of cobicistat and protease inhibitor atazanavir (atazanavir/cobicistat; marketed as Evotaz by Bristol-Myers Squibb).

Both Prezcobix and Evotaz were approved by the FDA in January 2015. Cobicistat is a potent inhibitor of cytochrome P450 3A enzymes, including the important CYP3A4 subtype. It also inhibits intestinal transport proteins, increasing the overall absorption of several HIV medications, including atazanavir, darunavir, and tenofovir alafenamide.

Chemistry

Cobicistat is a drug analogue of ritonavir, in which the valine moiety is exchanged for a 2-morpholinoethyl group, and the backbone hydroxyl group is removed. These changes effectively eliminate the anti-HIV activity of ritonavir while preserving its inhibitory effects on the CYP3A isozyme family of proteins.

Cobicistat is therefore able to increase plasma concentration of other coadministered anti-HIV drugs without the risk of causing cobicistat-resistant mutations in the HIV virus.

Synthesis

Cobicistat may be synthesized from any number of commercially available starting materials. The synthesis shown below utilizes L-methionine and bromoacetic acid as starting materials.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1329247274 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.